Evelo Biosciences, Inc. (NASDAQ:EVLO) Q4 2022 Earnings Call Transcript

Page 3 of 3

Peyton Bohnsack: Great. And then I guess, just could you kind of explain whether — how you’re thinking currently on whether you move forward with EDP1815 assuming the funding or a partnership deal is reached or would you kind of wait for a readout from EDP2939 in the second half of this year?

Simba Gill: Yes. So we’re working through all of that because there’s a couple of key components you touched on both of the rate picking. So one is

Peyton Bohnsack: Sorry, you broke up a little there. Do you mind repeating that for me?

Simba Gill: Sorry,  Actually, you broke up, so can you say that again?

Peyton Bohnsack: Sorry. So never mind, I’ll take it offline.

Operator: That concludes today’s question-and-answer session. I’d like to turn the call back to Simba Gill for closing remarks.

Simba Gill: Thank you very much, everyone. Appreciate everybody continuing to follow us. This is a very exciting time for us. And we look forward to updating you further on our clinical programs. And as we’ve talked about on this call, updates on EDP2939 in the EV program next level of efficacy and beyond. Thanks very much, everyone.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.

Follow Evelo Biosciences Inc. (NASDAQ:EVLO)

Page 3 of 3